LIQ861 Inhaled Treprostinil
Sponsors
Liquidia Technologies, Inc.
Conditions
Primary Pulmonary Hypertension
Phase 3
Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil
CompletedNCT03399604
Start: 2018-01-02End: 2019-11-25Updated: 2024-07-30
Extension Study for Participants in LIQ861 Trials to Evaluate the Long-term Safety of Dry Powder Inhalation of Treprostinil
Active, not recruitingNCT03992755
Start: 2019-07-18End: 2025-05-31Updated: 2025-01-29